Objectives A few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.
INTRODUCTION
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic and disabling immune-mediated polyradiculoneuropathy. [1] Several clinical variants of CIDP have been reported widening the spectrum of this neuropathy. These variants have been defined by the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society (EFNS/PNS) as 'atypical CIDP', and include distal acquired demyelinating symmetric neuropathy (DADS), purely motor or sensory CIDP, Lewis-Sumner syndrome (LSS) and focal CIDP. [1] The diagnostic criteria for these forms are however not well defined possibly explaining their variable frequency ranging from 1 to 49% in different series [2, 3] and the reported differences in their treatment response. [4] [5] [6] [7] It is also unclear the frequency and time to their possible evolution to typical CIDP. [5, 8] We established a set of diagnostic criteria for the CIDP variants derived from a revision of the literature and applied it to a large series of patients with CIDP included in a web-based database on Italian CIDP patients, to determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and their treatment response.
PATIENTS AND METHODS

Database and study population
From January 2015 to April 2018 we included data from 500 patients with a diagnosis of CIDP or one of its variants followed by 22 Italian Centers with expertise in immune-mediated neuropathies.
The diagnosis of CIDP was made by the treating neurologist and reviewed by the coordinating Centre (PED and ENO) and classified according to the EFNS/PNS diagnostic criteria. [1] The reasons for suspecting CIDP when nerve conduction studies were not diagnostic were also reported by the treating neurologist and included, beside a clinical history and presentation consistent with CIDP, abnormality of the supportive tests [1] (CSF analysis, ultrasound or magnetic resonance imaging -MRI-of the nerves and plexus, sensory conduction studies or somatosensory evoked potentials, nerve biopsy and response to previous therapy) and a relapsing course of the disease. All the data were included by the treating neurologist in a web-based electronic database expressly prepared by CINECA, Bologna, Italy. Informed consent was obtained from all participants at enrollment.
Diagnosis of atypical CIDP
We reviewed the literature on the diagnostic criteria used for atypical CIDP (supplementary   table 1) , and defined a set of clinical diagnostic criteria for all the patients included in our study (table 1) . Our criteria include mandatory and exclusion criteria for each atypical CIDP form while symptoms and signs not essential for the diagnosis (but that may be part of the clinical picture) were defined as 'other possible symptoms and signs'. We also decided that a minimum of one-year duration of symptoms and signs specific to each atypical form was necessary to establish a diagnosis of atypical CIDP. This because even typical CIDP may initially present with purely sensory or motor symptoms evolving over few months to a typical sensorimotor form. We defined purely sensory CIDP as a non-length dependent sensory neuropathy, DADS as a length-dependent sensory or sensorimotor neuropathy. Since however some authors included length-dependent purely sensory neuropathy as sensory CIDP we also separately analyzed the data of patients with sensory or sensorimotor DADS. We defined LSS as a sensory or sensorimotor multifocal neuropathy or in the presence of a clearly distinct degree of impairment among contiguous nerves. We included under this form focal CIDP where symptoms were homogeneously restricted to the nerves of one limb or two limbs (ipsilateral upper and lower limb). For chronic immune sensory polyradiculopathy (CISP) we used the criteria proposed by Sinnreich M. and coworkers. [9] Depending on the distribution of symptoms, patients with only sensory impairment were therefore split in our study into pure sensory CIDP including CISP, pure sensory DADS or pure sensory LSS.
We adhered to the criteria of the EFNS/PNS [1] for the diagnosis of typical CIDP but we also included under this diagnosis patients with bilateral, although asymmetric, but not multifocal, motor and sensory impairment (at least one MRC point difference between the two sides). 
Statistical analysis
Descriptive statistics were reported for the entire sample of patients with CIDP, and for typical and the atypical CIDP forms separately. Categorical variables were described using frequencies and percentages, while continuous variables using mean, medians, and ranges. Demographic, clinical and neurophysiological features, treatment response, strength deficit, disability level and quality of life were compared between different subgroups of patients with the chi-square or the Fisher's exact test for categorical variables, and with the t-test or the Wilcoxon-Mann-Whitney test for continuous variables. For patients with atypical CIDP at onset, the progression rate from atypical to typical CIDP was calculated using Kaplan-Meier survival curves, considering the different atypical forms separately. All tests were two-tailed and the significance level was set to 0.05. Analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Frequency and clinical course of atypical CIDP
By April 2018, 500 patients were enrolled in the database. Twenty-three patients were excluded from the analysis for the presence of an alternative diagnosis (18 patients with anti-MAG titers ranging from 9,300 to over 70,000 BTU, median 41,191 BTU), one with Charcot-Marie Tooth 1A, three with amyloidosis, and one with only cranial nerve palsy), and 17 for the absence of available nerve conduction studies or incomplete data. A total 460 patients were included in the study (293 men; 167 women), aged 11-92 years, (mean 58; median 60 years), with mean disease duration of (57.5%) with purely motor CIDP, 12/29 (41%) with LSS, and 3 with cranial CIDP. Figure 2 shows the yearly progression rate to typical CIDP for patients with different atypical CIDP forms at onset.
The clinical form with the highest progression rate was pure sensory CIDP, while DADS showed the lowest rate. Within 5 years, 48% of sensory CIDP patients, 32% of pure motor, 36% of LSS and 24% of DADS had progressed to typical CIDP; the corresponding values at 10 years were 77%, 64%, 63% and 39% (figure 2). Patients with atypical CIDP who progressed to typical CIDP had longer disease duration compared to patients who did not progress (mean, 11 vs 7 years; p=0.0016).
Clinical and electrophysiological features of the different forms of atypical CIDP
In Twenty-four (70.5%) patients met the EFNS/PNS diagnostic criteria for CIDP (21 definite, three probable). Seven of them had increased motor DL. Even if there were some differences between patients with (7 patients) or without (17 patients) increased motor DL in terms of frequency of upper-limb involvement (28.5% vs 47% patients; p= 0.6921) and presence of weakness (14% vs 41% patients; p= 0.6417), none of the differences was significant. 
PURELY SENSORY CIDP.
Sixteen patients had a diagnosis of purely sensory CIDP at study entry including two with CISP. In three patients sensory symptoms were confined to the upper limbs, in three patients to the proximal and distal areas of the lower limbs, in nine patients to the four limbs, and in one patient to the face -trunk and the four limbs. Strength was normal in all patients. Ataxia and fatigue were reported by three (19%) and four (25%) patients, respectively. The clinical course was relapsing in seven (44%) patients, progressive in eight (50%) patients and monophasic in one.
Twelve (75%) patients met the EFNS/PNS diagnostic criteria for CIDP (11 definite, one probable) with demyelinating features on motor conduction studies despite the absence of motor symptoms and signs.
No significant difference between purely sensory and typical CIDP was found in terms of severity assessed with INCAT (mean, 1.7 vs 2.7; p= 0.0532) and I-RODS (mean, 38 vs 33; p= 0.0799), and QoL (mean, 7 vs 8; p= 0.1310).
PURELY MOTOR CIDP.
Seventeen patients had a diagnosis of purely motor CIDP at study entry. 
Response to therapy in atypical CIDP
In table 2 is summarized the response to treatment in patients with atypical CIDP. Response to one or more therapy was reported in 16/25 (64%) treated patients with DADS including 9/15 (60%) fulfilling the EFNS\PNS criteria. There was no difference in treatment response between DADS patients with sensory or sensorimotor disturbance and between DADS patients with or without increased motor DL. Response to therapy occurred in 9/10 (90%) treated patients with sensory CIDP including 8/8 (100%) fulfilling the EFNS/PNS criteria. Improvement was also observed in 15/17 (88%) treated patients with purely motor CIDP, including 14/15 (93%) patients fulfilling the EFNS/PNS criteria. There was no difference in the overall response to therapy between patients with purely motor CIDP with or without abnormal sensory nerve conduction studies. Response to steroids was also observed in 3/7 (43%) patients with purely motor CIDP patients. None of the patients with normal sensory nerve conduction studies improved however after steroid therapy while all improved patients had abnormal sensory conduction studies. Response to therapy was reported in 9/14 (64%) treated patients with LSS, including 7/11 (63%) patients fulfilling the EFNS/PNS criteria. There was no difference between LSS patients with or without CBs.
Compared with typical CIDP, the overall response to treatment was significantly lower in patients with DADS (p= 0.0050) and LSS (p= 0.0326) even when we restricted the analysis to patients fulfilling EFNS/PNS criteria that in all but one patient with LSS and two with typical CIDP were consistent with definite or probable CIDP (table 2). The same occurred for patients with purely sensory DADS (p= 0.0109) but not for patients with purely sensory (p= 1.000) or purely motor CIDP (p= 0.7182). Patients with DADS and LSS also had a less frequent response to IVIg (p= 0.0178 and p= 0.0086) compared to typical CIDP and the same occurred for patients fulfilling EFNS/PNS criteria even if the difference remained significant only for LSS (table 2) . A less frequent response to IVIg was also observed in patients with sensory DADS (p= 0.0108) but not in patients with pure motor o pure sensory CIDP. There was no difference among the different groups in the response to steroids. Among the patients with typical CIDP, 235 (62.5%) patients had symmetric CIDP while 141 (37.5%) an asymmetric but not multifocal CIDP (> 1 MRC point difference between the two sides), and 36 (9.5%) patients had slightly asymmetric (but not multifocal) CIDP (1 MRC point difference between the two sides). There was no difference between patients with symmetric or asymmetric CIDP in the overall response to therapy (87% vs 87%; p= 1.0000) or in the response to IVIg (78% vs 78%; p= 1.0000) or steroids (48% vs 56%; p= 0.3533) while the difference in the overall response to treatment (p= 0.0384) and to IVIg (p= 0.01) remained significant between patients with either symmetric or asymmetric typical CIDP and LSS.
(Verifica i dati)
DISCUSSION
There is some discrepancy on the frequency of the CIDP variants with numbers ranging from 1 to 49%. [2, 3] It is unclear whether this discrepancy reflects the use of different diagnostic criteria in previous studies or a different disease duration at the time of ascertainment. There are indeed some differences in the definition of these phenotypes. We applied our set of diagnostic criteria to all our patients and found that the frequency of atypical CIDP at study entry was 18%, similarly to some previous studies (17.8-19 .6%). [10, 11] When we retrospectively analyzed the symptoms at the time disease onset and for the following year, we found that 39% of the patients had a clinical presentation consistent with atypical CIDP that in 53% of the patients evolved to typical CIDP by the time of inclusion in the study. A similar rate of progression (20-71%) was previously reported in other small series of patients. [5, 8, 12] In our study, progression to typical CIDP was significantly associated with a longer disease duration. Still, 55% of our patients with atypical CIDP at study entry had a disease duration of at least 5 years and 30% of at least 10 years. This finding supports the idea that progression to typical CIDP is often, though not invariably, associated with the disease duration. Some patients with typical CIDP presented some clinical modifications during the course of the disease leading to a predominantly distal or sensory but not motor or multifocal impairment, even if the previously more diffuse and sensorimotor impairment did not lead to a change in their diagnosis. There are also some differences in the reported frequency of the different forms of atypical CIDP. The relatively small prevalence of LSS in our series (4%) compared to some previous series (0.5-34%) [3, 6, 10, 11, 13] may reflect the inclusion in our series of only patients with a multifocal neuropathy and not of those with an asymmetric polyneuropathy. This decision was also supported by the absence of difference in the response to therapy between patients with symmetric or asymmetric typical CIDP, and by the finding that almost 40% of the patients with typical CIDP in our cohort had some degree of asymmetry, a figure that is more indicative of a typical form rather than an atypical form. Similarly, we found a lower prevalence of sensory CIDP (3.5%) compared to previous series (11-35%) . [14, 15] This may partly reflect our use of stringent diagnostic criteria with the proportion of patients raising to 7.8% if we also included patients with purely sensory DADS or LSS. It is also possible that the disease duration explains the difference with a prevalence of sensory CIDP in our series decreasing from 11% at onset to 3.5% at enrollment. DADS was the most common CIDP variant in our study (7%), (2-17% in previous studies), [2, 6, 10] followed by the purely motor form (4%) (4-10% in previous series). [2, 10, 13] Only few studies have compared disability in typical and atypical CIDP. [6, 30, 31 ] Two studies found a higher level of disability and impairment in typical CIDP than in LSS and DADS patients. [6, 30] Another study did not find difference in terms of disability between typical and atypical CIDP. [31] In our series, patients with typical CIDP had a worse MRC score, higher disability and worse QoL than patients with DADS, confirming that DADS is clinically less disabling than typical CIDP. Patients with LSS had less severe disability than patients with typical CIDP by I-RODS but not by INCAT. This discrepancy may reflect the wider range of item difficulties in the I-RODS than INCAT scale. On the other hand we did not find differences in the degree of motor impairment, disability and QoL between purely motor CIDP patients and typical CIDP patients. Similarly, disability and QoL where similar in sensory and typical CIDP.
There are some differences in the reported response to therapy in patients with atypical CIDP. A better response to IVIg than to steroids was reported in some series of patients with LSS, [4, 5, 7, 16, 17] while others [6] reported a reduced response to IVIg but not to steroids compared to typical CIDP. Patients with DADS were reported to have a less satisfactory response to treatment than patients with typical CIDP. [18, 19] In our series, patients with LSS and DADS had a less frequent response to therapy (p= 0.0326; p= 0.0050) and to IVIg (p= 0.0086; p= 0.0178) compared to patients with typical CIDP and the same occurred for patients with purely sensory DADS, while there was no differences in the response to steroids.
Several reports suggest that purely motor CIDP may not respond to or even worsen after corticosteroids. [20, 21] Based on these findings, the EFNS/PNS Guidelines recommend the use of IVIg for motor CIDP. [1] However, response to steroids has been reported in other studies, with figures up to 20% of treated patients. [13] We found that 43% of our purely motor CIDP patients improved after steroids. All these patients had however a concomitant sensory electrophysiological, although not clinical, impairment. This finding suggest that the diagnosis of motor CIDP and the decision to avoid steroids should be probably restricted to patients without any clinical and electrophysiological involvement of motor nerves. Only few data are available on the response to therapies in patients with purely sensory CIDP with a usually favourable response to both IVIg and steroids. [13, [22] [23] [24] We also found a similar response rate in comparison to patients with typical CIDP.
In conclusion, our study on a large population of patients classified according to a uniform set of diagnostic criteria, confirms that the proportion of patients with atypical CIDP varies according to the duration of the disease and that response to therapy is different in some of these forms (DADS and LSS). The persistence of an atypical presentation in a consistent proportion of patients for several years together with the different response to therapy in some of these forms, suggest that some difference in the pathogenic mechanisms may underlie some of these variants. An extensive immunological study to investigate the presence of different anti-nerve antibodies is in progress in this cohort of patients to verify whether the different clinical presentations and response to therapy might be associated with specific immunological abnormalities as was recently reported for patients with antibodies to neurofascin 155, contactin 1 and other nodal-paranodal proteins. [32, 33] It would be also advisable to verify these data in a prospective study on a large series of newly diagnosed patients in whom a definite set of diagnostic criteria and of diagnostic investigations and assessment would be applied and subsequently periodically verified. [34] Graph shows the yearly progression rate to typical CIDP of the individual atypical CIDP forms at onset.
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